Merck finds drug discovery DALL-E, becoming early user of small molecule generative AI tool

[cafead]

via Merck & Co. is taking a look at a generative AI platform. As an early user of Variational AI’s technology, the Big Pharma will assess the ability of the platform to generate novel small molecules that match its target product profiles (TPPs).

article source